We rely on your tax-deductible donations to support our mission. Donate online →
Most Policy Initiative logo
Browse Research TOPICS

Step Therapy Outcomes in Advanced Cancer

Written by Dr. Jennifer Bean
Published on October 19, 2026
Research Highlights

Step therapy is a cost saving mechanism that requires patients to try cheaper drugs before the ones originally prescribed. 

Healthcare insurers are increasing their use of step therapy.  

Step therapy therapy’s effect on outcomes and healthcare spending for advanced cancer is unknown.

Step therapy use is rising. 

Step therapy is a cost-lowering strategy where an insurance company requires a patient to try a less expensive drug before the one originally prescribed. It is commonly used to manage chronic diseases, like rheumatoid arthritis, psoriasis, and Crohn’s disease (Shan et al. 2024, Tharp & Rothblatt 2022).  

Advanced cancer describes cancer that is unlikely to be cured (American Cancer Society (ACS) 2025). It includes cancer which has grown into nearby tissue (locally advanced) or spread to another part of the body (metastatic). Treatment options narrow with each new treatment attempted, and outcomes are time sensitive (Le et al. 2020). Some advanced cancers can be treated as chronic diseases and managed with long-term drug use to shrink the cancer, slow its growth, and relieve symptoms (ACS 2025).  

Among health plans covering 70% of the commercial insurance market, use of cost-lowering strategies for cancer drugs rose from 15% of insurance decisions in 2017 to 23% in 2024 (Rucker et al. 2026, Figure 1). Specifically, step therapy use rose from 4% in 2017 to 17% in 2024. About three-quarters of cancer patients required to use step therapy must try a generic or biologically similar drug, while one-quarter must try a different brand-name drug before insurers pay for the originally prescribed treatment.  

Figure 1. Change in commercial insurance decisions about cancer drugs. Insurers used cost-lowering strategies more in 2024 (22.9%) than in 2017 (14.5%). The percentage of patients required to use step therapy (yellow) rose from 4.3% in 2017 to 16.5% in 2024. The effect of step therapy on health outcomes and healthcare spending in advanced cancer is unknown. Adapted from Rucker et al. 2026.  

The effect of step therapy on health outcomes in advanced cancer is unknown. 

Specific outcome data on step therapy use in advanced cancer is not available for commercial insurance, Medicare, or Medicaid. However, healthcare workers who treat cancer have reported care disruptions, including wasted medication, higher chance of avoidable complications, and delayed treatment (Hamad et al. 2026). A four-week delay in treatment was linked to increased mortality across multiple cancers (Hanna et al. 2020).  

In other chronic diseases, like rheumatoid or psoriatic arthritis, patients required to use step therapy were 20 – 30% less likely to have effective treatment compared with those whose insurance did not require it (Shan et al. 2024).  

The effect of step therapy on healthcare spending in advanced cancer is unknown. 

The effect of step therapy on healthcare spending in advanced cancer is not known. In other chronic conditions, step therapy has increased insurer-paid costs. One modeled analysis found Crohn’s disease patients who did not respond to their required step therapy drug created 37% more insurer-paid costs than in the model with no step therapy (Tharp & Rothblatt 2022). Data on how many advanced cancer patients do not respond to their first step therapy drug is not available.

References 

American Cancer Society (2025) What Are Advanced and Metastatic Cancers? https://www.cancer.org/cancer/understanding-cancer/what-is-cancer/advanced-and-metastatic-cancer.html  

American Cancer Society (2025) If Cancer Treatments Stop Working. https://www.cancer.org/cancer/making-treatment-decisions/if-cancer-treatments-stop-working.html  

Center for Medicare and Medicaid Services (CMS) (2018) Medicare Advantage Prior Authorization and Step Therapy for Part B Drugs. U.S. Department of Health and Human Services. https://www.cms.gov/newsroom/fact-sheets/medicare-advantage-prior-authorization-step-therapy-part-b-drugs  

Hamad L, Page C, Berman M (2026) Understanding Oncology Step Therapy in Medicare Part D: Considerations for Life Science Companies. Milliman. https://www.milliman.com/en/insight/understanding-oncology-step-therapy-in-medicare-part-d  

Hanna TP, King WD, Thibodeau S, Jalink M, Paulin GA, et al. (2020) Mortality Due to Cancer Treatment Delay: Systematic Review and Meta-Analysis. The British Medical Journal 371:m4087. https://www.bmj.com/content/371/bmj.m4087  

Le DT, Ott PA, Korytowsky B, Le H, Le TK, et al. (2020) Real-World Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients with Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. Clinical Colorectal Cancer 19(1):32-38.e3. https://pubmed.ncbi.nlm.nih.gov/31813769/  

Rucker JA, Beinfeld MT, Enright D, Liljas B, Chambers JD (2026) Trends in Utilization Management for Oncology Therapies Amongst U.S. Commercial Health Plans: 2017 – 2024. Journal of Oncology Practice 00:1-8. https://ascopubs.org/doi/10.1200/OP-25-01096 

Shan DM, Greenzaid JD, Greene E, Feldman SR (2024) Analyzing the Benefits and Costs of the Safe Step Act on Patients, Physicians, and Insurers. Journal of Psoriasis and Psoriatic Arthritis 9(3):115-120. https://journals.sagepub.com/doi/10.1177/24755303241253203  

Tharp L, Rothblatt Z (2022) Do Patients Benefit from Legislation Regulating Step Therapy? Health Economics, Policy, and Law 17(3):282-297. https://pubmed.ncbi.nlm.nih.gov/33843568/  

Most Policy Initiative logo
Contact
238 E High St., 3rd Floor
Jefferson City, MO 65101
314-827-4549
info@mostpolicyinitiative.org
Organization
© 2026 MOST Policy Initiative | Website design and development by Pixel Jam Digital
Privacy Policy
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram